BIOCAD

BIOCAD is a Russia-based, vertically integrated drug discovery, development, and manufacturing company.

The company says it has over 50 products in its portfolio, of which 10 are "biotechnological products."

• Rituximab biosimilar, chimeric monoclonal antibody which specifically binds to the transmembrane antigen CD20. Indications: non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Currently >60 000 patients treated, >650 000 vials sold, marketed in 14 countries. This drug is sold by BIOCAD under the trade name Acellbia.
• Bevacizumab biosimilar, recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Indications: colorectal cancer, ovarian and cervical cancer, lung cancer, renal cell cancer, glioblastoma, breast cancer. Currently >10 000 patients treated, >332 000 vials sold, marketed in 9 countries under the trade name Avegra
• Trastuzumab biosimilar, recombinant humanized IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2) that has been shown to inhibit the proliferation of HER2 overexpressing cancer cells.

• Infliximab is a tumour necrosis factor alpha (TNFα) inhibitor, the first-line biologic therapy in patients with a number of immune-mediated inflammatory diseases: rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease and ulcerative colitis, psoriasis and psoriatic arthritis.
• Interferon beta-1b, the first Russian human recombinant interferon beta-1b used in the treatment of multiple sclerosis. Launched in 2009.

The company says it has over 40 products under development.

BIOCAD is currently developing a mRNA vaccine for SARS-CoV-2, the virus which causes COVID-19.

• anti PD-1 mAb, in Phase II trials
• CDK8 inhibitor, in Phase II trials
• anti CTLA4 MAB, in Phase I trials
• anti PD-L1 mAb, in Phase I trials
• anti CD47 mAb, in Phase I trials
• anti CD20 mAb, in Phase I trials
• anti C-MET mAb, in pre-clinical studies

• adalimumab, which is in the registration phase
• anti IL-17 mAb, in Phase III trials
• Tenexia® (pegylated interferon beta-1a), in Phase II trials
• anti IL-6R mAb, in Phase II trials
• anti CD20 mAb, in Phase I trials
• anti IL-5R mAb, in pre-clinical studies

• anti PCSK9 mAb, in Phase I trials

BIOCAD is headquartered in Saint Petersburg, Russia. It has other Russian offices as well: one in Moscow and another in the Skolkovo Innovation Center, which is located just outside Moscow. BIOCAD has international offices in Belarus, India, China, Brazil, and the United States.

BIOCAD says it has over 2,200 employees distributed across its offices around the world. 40% of its employees are scientists, according to the company.